3 research outputs found
Insights into Ordinal Embedding Algorithms: A Systematic Evaluation
The objective of ordinal embedding is to find a Euclidean representation of a
set of abstract items, using only answers to triplet comparisons of the form
"Is item closer to the item or item ?". In recent years, numerous
algorithms have been proposed to solve this problem. However, there does not
exist a fair and thorough assessment of these embedding methods and therefore
several key questions remain unanswered: Which algorithms scale better with
increasing sample size or dimension? Which ones perform better when the
embedding dimension is small or few triplet comparisons are available? In our
paper, we address these questions and provide the first comprehensive and
systematic empirical evaluation of existing algorithms as well as a new neural
network approach. In the large triplet regime, we find that simple, relatively
unknown, non-convex methods consistently outperform all other algorithms,
including elaborate approaches based on neural networks or landmark approaches.
This finding can be explained by our insight that many of the non-convex
optimization approaches do not suffer from local optima. In the low triplet
regime, our neural network approach is either competitive or significantly
outperforms all the other methods. Our comprehensive assessment is enabled by
our unified library of popular embedding algorithms that leverages GPU
resources and allows for fast and accurate embeddings of millions of data
points
Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
Multiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM is modernized with the introduction of newer therapeutics agents, i.e., target-specific monoclonal antibodies. The currently available literature lacks the benefits of newer targeted therapy being developed with an aim to reduce side effects and increase effectiveness, compared to conventional chemotherapy regimens. This article aims to review literature about the current available monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies for the treatment of MM
Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma.
Multiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM is modernized with the introduction of newer therapeutics agents, i.e., target-specific monoclonal antibodies. The currently available literature lacks the benefits of newer targeted therapy being developed with an aim to reduce side effects and increase effectiveness, compared to conventional chemotherapy regimens. This article aims to review literature about the current available monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies for the treatment of MM